MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
PORTLAND, Ore., June 12, 2017 -- Nobilis Therapeutics announced today that the patent that it had exclusively licensed from Partners HealthCare/McLean Hospital (an affiliate of Harvard University) has received a notice of allowance. The patent is titled "XENON AND/OR ARGON TREATMENT AS AN ADJUNCT TO PSYCHOTHERAPY FOR PSYCHIATRIC DISORDERS" and covers a wide range of noble gas uses in the treatment of psychiatric disorders.
"We are very pleased to receive this very exciting news," said Dr. Vlad Bogin, company's CEO. "This patent had laid the groundwork for our first therapeutic indication, which is post-traumatic stress disorder (PTSD). As Nobilis Therapeutics has selected the 505(b)(2) pathway to NDA approval, having an issued patent becomes of paramount importance."
"The issue of a patent from the United States Patent and Trademark Office strongly supports the novelty of our safe approach to treating this debilitating and devastating condition - more than 20 Veterans a day commit suicide as they try to cope with their traumatic experiences. Sadly, current therapies and treatments are only moderately effective. We are very excited to have forged this relationship with Nobilis Therapeutics as we work to translate our research findings into a clinical trial and, hopefully, an effective treatment for PTSD," said Edward Meloni, Ph.D., one of inventors.
About Nobilis Therapeutics, Inc.
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases that have an exceptional safety profile proven by decades of clinical use. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has successfully used this technology in the treatment of over 500 patients for conditions ranging from panic attacks to substance abuse.
Vlad Bogin, MD, FACP 3042NW Monte Vista Terrace Portland, OR 97210 Tel: (971) 229-1679 Email: [email protected] Website: http://www.nobilistx.com Twitter: @nobilistx
